Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glisolamide SCHEMBL27735549 | 0.90 | CYP3A4 (0.62) | LMNAALDH1A1MAPTCYP3A4NFKB1 | |
| SCHEMBL23893971 | 0.89 | LMNA (0.53) | LMNAALDH1A1MAPTCYP3A4NFKB1 | |
| Glisoxepide SCHEMBL28142826 | 0.86 | LMNA (0.57) | LMNAALDH1A1MAPTCYP3A4NFKB1 | |
| Glisolamide SCHEMBL38106 | 0.84 | LMNA (0.73) | LMNAALDH1A1MAPTCYP3A4NFKB1 | |
| SCHEMBL11630344 | 0.81 | ALDH1A1 (0.63) | LMNAALDH1A1MAPTCYP3A4NFKB1 | |
| Glimepiride SCHEMBL28086735 | 0.80 | CYP2C9 (0.72) | LMNAALDH1A1MAPTCYP3A4NFKB1 | |
| SCHEMBL11628147 | 0.80 | ALDH1A1 (0.53) | LMNAALDH1A1MAPTCYP3A4NFKB1 | |
| SCHEMBL18007638 | 0.80 | NLRP3 (0.58) | LMNANLRP3 | |
| SCHEMBL11627816 | 0.80 | MAPT (0.57) | LMNAALDH1A1MAPTCYP3A4NFKB1 | |
| SCHEMBL11624368 | 0.79 | ALDH1A1 (0.53) | LMNAALDH1A1MAPTCYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4356 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4640701-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-10-29 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4520343-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP1)-GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-03-12 | — | — | EP | claimed |
| EP-3988123-B1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-26 | — | — | EP | claimed |
| US-12208071-B2 | Glucagon receptor antagonists | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2025-01-28 | — | — | US | claimed |
| US-12186329-B2 | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-01-07 | — | — | US | claimed |
| US-20240366579-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-11-07 | — | — | US | claimed |
| US-20240316048-A1 | Prevention of Pancreatic Cell Degeneration | MELIOR PHARMACEUTICALS I, INC. | 2024-09-26 | — | — | US | claimed |
| US-12070461-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-08-27 | — | — | US | claimed |
| EP-4329756-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2024-03-06 | — | — | EP | claimed |
| WO-1998036755-A1 | SULFONYLUREA-GLITAZONE SYNERGISTIC COMBINATIONS FOR DIABETES | WARNER LAMBERT COMPANY (US) | 1998-08-27 | — | — | WO | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| CN-1170346-A | Process for encapsulation of caplets in capsule and solid dasage forms obtainable by such process | WARNER LAMBERT CO (US) | 1998-01-14 | — | — | CN | claimed |
| WO-1997037629-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-16 | — | — | WO | claimed |
| EP-0797424-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-01 | — | — | EP | claimed |
| EP-0724427-A1 | HIGHLY ACTIVE SULPHONYL UREA PREPARATIONS EXHIBITING RAPID OR CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE, AND METHOD OF PRODUCING THEM | BRITISH TECHNOLOGY GROUP LTD (GB) | 1996-08-07 | — | — | EP | claimed |
| WO-1996018370-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1996-06-20 | — | — | WO | claimed |
| WO-1995011006-A1 | HIGHLY ACTIVE SULPHONYL UREA PREPARATIONS EXHIBITING RAPID OR CONTROLLED RELEASE OF THE ACTIVE SUBSTANCE, AND METHOD OF PRODUCING THEM | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1995-04-27 | — | — | WO | claimed |
| US-4708868-A | Oral anti-diabetic pharmaceutical forms and the preparation thereof | DR. KARL THOMAE GMBH (DE) | 1987-11-24 | — | — | US | claimed |
| US-4696815-A | Anti-diabetic pharmaceutical forms and the preparation thereof | DR. KARL THOMAE GMBH (DE) | 1987-09-29 | — | — | US | claimed |